MARKET

BVXV

BVXV

BiondVax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.90
-0.67
-3.26%
Closed 16:00 05/29 EDT
OPEN
20.42
PREV CLOSE
20.57
HIGH
20.60
LOW
18.55
VOLUME
65.15K
TURNOVER
--
52 WEEK HIGH
25.50
52 WEEK LOW
5.20
MARKET CAP
206.03M
P/E (TTM)
19.40
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BVXV stock price target is 30.00 with a high estimate of 30.00 and a low estimate of 30.00.

EPS

BVXV News

More
96 Biggest Movers From Yesterday
Gainers Mmtec, Inc. (NASDAQ: MTC) shares climbed 86.4% to close at $2.05 on Tuesday after reporting its financial results for the year ended December 31, 2019. Revenues jumped 647% to $200,797, in 2019.
Benzinga · 5d ago
71 Biggest Movers From Friday
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday after pricing its IPO on Friday.
Benzinga · 6d ago
Stocks That Hit 52-Week Highs On Friday
On Friday, 46 stocks hit new 52-week highs.
Benzinga · 05/22 14:31
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/22 09:26
51 Stocks Moving In Thursday's Mid-Day Session
Gainers Seneca Biopharma, Inc. (NASDAQ: SNCA) jumped 99% to $1.6350.
Benzinga · 05/21 17:18
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 48 companies set new 52-week highs.
Benzinga · 05/21 14:25
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.)
Benzinga · 05/21 12:01
BiondVax Announces Receipt Of $4.2M Through Exercise Of Warrants
Benzinga · 05/20 10:36

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About BVXV

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
More

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.